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Abstract: 
Gastric cancer is recognized as the fourth most common cancer in the world, and is the second leading cause of 
cancer death. PTEN is a tumor inhibitor gene. PTEN mutation is observed in most of the cancerous 
malignancies. In this study, the expression and common PTEN gene polymorphism in blood samples of patients 
with gastric cancer were studied using REAL TIME PCR and RFLP PCR techniques in Iranian population. 45 
blood samples (36 patients and 9 controls) were studied in this study. After extracting the RNA and confirming its 
quality, cDNA synthesis was performed and the expression of the gene was evaluated by qPCR. In order to 
investigate the single-nucleotide change in rs10490920, the DNA was extracted from the specimens and then 
PCR was performed. After obtaining ct, the samples RQ was analyzed and analysis of samples RQ showed that 
the PTEN Gene expression was reduced in patients compared with controls. In patients with rs10490920 
polymorphisms in the PTEN gene, the risk of the disease increased. The results of the study indicate a reduction 
in gene expression in cancer patients. Thus, it may be possible to use Pten gene expretion assesment as a possible 
biomarker in early diagnosis or in the treatment process. 
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INTRODUCTION: 
In Iran, stomach cancer Has the highest rate of 
cancers prevalence in men. In Iran, the malignancy 
is also known as the second cause of cancer deaths 
in men and women. Although the incidence of this 
cancer is lower in other areas of the world, the 
reasons for this difference are unclear. It is possible 
that the high rate of lethality in this cancer in Iran is 
related to its diagnosis in advanced stages of the 
disease, and this disease is more invasive in the 
Iranian population [1]. In recent decades, it has 
declined for making changes in lifestyle in 
developed It is possible that the high rate of 
lethality of this cancer in Iran is related to diagnosis 
in advanced stages and /or more aggressive 
behavior of tomor cells(1).recently the incidence of 
stomach cancer in developed countries is reduced 
due to changes in lifestyle such as the forbiddance 
of smoking and eradicating Helicobacter pylori [2]. 
Researches has shown that two types of genomic 
changes play a role in cancer development. 1. 
Changes causing the tumor suppressing genes to 
fail. 2. Changes that increase the gene or Changes 
that cause tumor suppression genes failure.(2) 
changes that lead to increasing the genetic products 
of oncogenic genes. PTEN is a tumor inhibitor 
gene. Most studies are evaluated PTEN in their 
negative regulation  function in the PI3K/AKT 
messaging pathway, which are involved in cell 
viability, proliferation, and inhibition of apoptosis 
[3]. A balanced limit for PTEN expression is vital 
for the cell. Reports indicate that the expression and 
the PTEN enzymatic activity can be regulated by 
microRNAs during transcription or afterwards [4]. 
PTEN mutation is seen in most of the cancerous 
malignancies. This mutation has been seen 
alternately in the last stage of glioblastoma, 
melanoma, prostate cancer, the first stage of thyroid 
cancer, and endometrial Endometrial and cervical 
cancer. This mutation has not been identified in 
other types of tumors [5]. The inactivation of PTEN 
can lead to the diversification of tumor cells and 
tissue. Reports indicate that inactivation of PTEN is 
associated with the spread of disease and the 
progression of gastric cancer [6]. PTEN expression 
in metastatic lymph nodes and advanced gastric 
cancer was significantly less than the non-
metastatic lymph nodes and primary stomach 
cancer. The PTEN expression level could be used 
as a pathologic diagnostic guide for gastric cancer 
[7]. Therefore, the purpose of this study was to 
detect rs10490920 polymorphism in PTEN gene 
and to investigate the association of this 
polymorphism with gastric cancer, to detect PTEN 
in serum of gastric cancer patients, to investigate 
the relationship between the amount of PTEN 
expression  in normal people and patients and the 
evaluation of using the PTEN expression level as a 
marker for diagnosis in order to screen in the early 
stages, which can be used In diagnosis and 
treatment if its efficacy and optimization is proved 
therapeutic and therapeutic diagnosis if it be 
efficacy. 
 
MATERIAL AND METHODS: 
Sample collection: For this study, 45 blood 
samples consist of 36 patients and 9 normal people 
were used. 5 ml of peripheral blood were taken 
from all people. Blood samples were collected in 
falcons containing EDTA at a final concentration of 
1 mg/ml. Samples were kept at -20 c° until full 
extraction. Sampling was conducted under 
supervision of the Ethics Committee of Shahid 
Beheshti University of Medical Sciences under the 
WHO (World Health Organization) criterion. The 
statistical analysis of the information extracted 
from the questionnaire was done by GraphPad 
software (GraphPad prism5). 
RNA extraction: For this purpose, an RNX PLUS 
solution was used according to the optimized 
protocol [8]. In order to investigate the quantity of 
RNA extracted from spectrophotometric apparatus 
and optical absorption in 280/260 nm was used. 
Synthesis of cDNA: At first, 10 microliters of RNA 
template, together with 1-microliter dntp 10Mm 
and 1 microliter of Random Hexamer, followed by 
1 microliter of oligo dt was mixed. The tube was 
placed at 65 c° for 5 minutes. Then, 2 μl of MMulv 
10 X buffer and 5.0 μM of MMulv enzyme were 
added to the mixture, finally added the water and 
the final volume reached 20 μl. Finally, the final 
tube was incubated at 42 c° for 1 hour.  
Design of specific primers for the GAPDH and 
PTEN genes: The GAPDH gene sequence used as 
internal control, as well as the PTEN gene gained 
from the NCBI gene database and specific primers 
was designed by primer express program. In order 
to confirm the specificity and precision of primers 
designed, their sequence was blasted into NCBI. 
The sequence of the listed primers include the 
target gene primers with the sequence of the 
ACAAGATATACAATCTTTGTGC PTEN Real 
time F /PTEN Real time R 
TCACAAAAGGGTTTGATAAG and the internal 
control sequences with sequences 
ATGGAGAAGGCTGGGGCT GAPDH (F) and 
GAPDH (R) 
ATCTTGAGGCTGTTGTCATACTTCTC were 
studied in this study. 
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Table 1: patient profile 
Sex 
Over 50 years 
old 
Under 50 
years old 
Healthy Patient Total 
Female Male 
57.77 % 42.22 % 20 % 80 % 100 % 
33.33% 66.66% 
Optimizing the essential factors of the real time -
PCR for the GAP DH and PTEN gene: For this 
purpose, separate reactions for the desired gene and 
internal control gene were made in the final volume 
of 20 μL. The reactions are laid out on the 
AB17500 in parallel. In each reaction, 10 μM 
SYBER TM (2X) and 10 μM Reverse and forward 
primer and c DNA template were used at a 
concentration of 2 μg. The thermal reaction is 1 
cycle at 95 c° for 10 minutes and 40 cycles with 2 
times 15 seconds and 56 seconds at 95 c° and 54.5 
c° and 1 cycle for 3 times 15 seconds, 1 minute and 
15 seconds at 95, 54 and 95 c° temperatures, 
amplification curve analysis was used to confirm 
the replicated fragment and to ensure the absence 
of non-specific product, dimer primer and 
contamination. After optimization, the RNA of all 
samples was extracted and after confirmation of the 
quality of the obtained RNAs and cDNA synthesis 
was performed on the samples. Ct of the samples 
were calculated by the setting after the proliferation 
reaction and converted to RQ or expression level, 
and then the measurement of the gene expression 
was performed using the ΔΔct method. The 
expression level of patient samples was expressed 
in comparison with normal samples. After the 
reaction, the raw data was extracted from ct by the 
setting and the expression rate was measured using 
the ΔΔct method. Then, the gene expression chart 
was drawn up using the Graph pad software. 
DNA extraction: The DNA of the samples were 
optimized by the protocol and was obtained DNG 
solution. After extraction, the quality of DNA was 
evaluated by spectrophotometer. 
PCR: For proliferation of the fragment containing 
rs10490920 were used PTEN RFLP F 
TCAAGAAGTCCAAGAGCATT / PTEN RFLP R 
AGACAAGACAAGCCACCTAA primers [23]. 
First, 12.5 μL Master Mix was mixed with 1 μL 
Reverse Primer and 1 μL Forward Primer and 5.5 
μL DDW and 5 μL of the template DNA. The 
thermal reaction was consist of  1 cycle at 93 c° for 
3 minutes and 40 cycles 3 times 30 seconds at 93, 
59±5, 72 c° and 1 cycle and 72 c° for 5 minutes, 
and the agarose gel 1.5% was placed for ensuring 
that the PCR was performed correctly. To perform 
the RFLP reaction, the NOCI restriction enzyme 
was added to products. First, 2μL 10X Buffer 
Tango were mixed with 2 μl NOCI restriction 
enzyme and 10 μl PCR product and 18 μl of DW. 
The thermal reaction was consist of 16 hours 
incubation at 65 c° and 20 minutes of inactivation 
at 80 c°. After RFLP, the agarose gel 2.5% was 
placed for investigating the presence of 
polymorphism in samples. The relationship 
between rs10490920 polymorphism and gene 
expression was measured by 1wayANOVA test. 
 
Results: 
In this study, in order to investigate the specificity 
of primers and color of fluorescence (syber green) 
and to ensure the replication of specific fragment 
and to verify the absence of non-specific 
components in the PCR product, the melting curve 
diagram for the PTEN gene and GAPDH (Diagram 
1) were drawn separately by the Real Time PCR 
(ABI7500), which confirms the correct binding of 
the primers to the PTEN gene and the product was 
obtained that is desired for the gene. After the 
replication reaction, ct of the samples were 
calculated by the setting and converted to (RQ) 
Relative Quantization and the expression level was 
measured by ΔΔct method. The expression level of 
the patient samples was compared with normal 
samples. RQ of the samples was removed from the 
setting and the results were plotted by Graph pad 
software (Diagram 2). The comparison of PTEN 
gene expression level in patient and normal 
samples (9 normal samples have been converted to 
a sample in average in this diagram). Most of the 
expressions belongs to samples of 7, 10, 11 and 30. 
1, 12, 14, and 24 samples have the lowest 
expression, which is likely to be at high stage of 
cancer. The RQ shown in the chart is the RQ mean 
of the patient and control groups. As shown in 
Diagram 3, the expression level of the gene in the 
patient group is reduced in comparison with the 
control group (Diagram 3). Also the mean of PTEN 
gene expression in men is higher than women 
(Diagram 4). The PTEN gene expression level in 
the 55-year-old group is lower than the 55-year-old 
group (Diagram 5). To ensure the quality and purity 
of the extracted DNA, the samples were 
electrophoresed in the agarose gel 1.5% (Fig. 1). 
The PCR product was prolonged using the primers 
used for 334bp, which was confirmed in the 
agarose gel. After enzyme treatment, homozygous 
CC samples with molecular weights of 334bp have 
3 bands, heterozygote CT specimens with 
molecular weight of 194bp have 2 bands, and 
homogeneous TT samples with molecular weight 
of 174bp have 2 bands. As shown in Fig. 2. NOCI 
restriction enzyme were added to the PCR products 
and all samples were electrophoresed in agarose gel 
2.5%. Homozygote CC samples with molecular 
weight of 334bp have 3 bands, heterozygote CT 
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specimens with molecular weight of 194bp have 2 
bands, and homogeneous TT samples with  
molecular weight of 174bp have 2 bands. As shown 
in Diagram 6, the expression of the CT genotype 
decreased compared to other two genotypes. The 
CC normal genotype shows a higher expression 
level (Diagram 7). As shown in Diagram 8, the CT 
heterozygote genotype has been reduced to the 
other genotypes. 
 
 
  
                               GAPDH                                                               PTEN 
Diagram 1. Analysis of the melting curve of PTEN and GAPDH genes 
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Diagram 2: The level of PTEN gene expression in the patient and control groups. RQ shows the PTEN gene 
expression level in comparison with the normal sample. The numbers represent the sample number (P=0.7587). 
 
Diagram 3. Comparison of the gene expression in the patient and control groups. The mean of expression level 
in patient and normal groups were 2.74 and 4.91, respectively (P= 0.04). 
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Diagram 4. Comparison of mean gene expression with sex: The average of expression level in women's and 
men's group were 1.55 and 7.77, respectively (P=0.04). 
 
 
 
Diagram 5. Comparison of PTEN gene expression level in different age groups: The mean of gene expression 
rate in the group under 55 years of age and the group over 55 years old were 3.15 and 8.85, respectively 
(P=0.012). 
 
Figure 1. Agarose gel electrophoresis 1.5%. Ladder (50bp fermentas) 
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Figure 2. Agarose gel electrophoresis of PTEN gene. 1: ladder (50bp fermentas) 5: PCR product of patient 
sample, 6: PCR product control sample 
 
Diagram 6. Comparison of the expression level in 3 genotypes: The mean of expression rate in CC genotype 
and CT genotype ct: 2.91 and TT genotype are 7.80, 2.91 and 8.60, respectively (P=0.00). 
 
Diagram 7. Comparison of PTEN gene expression with 3 above genotypes for people under 55 years old: The 
expression level average in the TT genotype, CC genotype and CT genotype are 4.66, 6.49 and 2.42, 
respectively (P=0.01). 
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Diagram 8. Comparison of PTEN gene expression with 3 above genotypes for people above 55 years old: The 
expression level average in the TT genotype, CC genotype and CT genotype are 9.02, 7.84 and 4.30, 
respectively (P=0.02). 
 
DISCUSSION: 
The PTEN protein in its catalytic region contains a 
very similar sequence to cellular skeletal proteins 
such as Tensin and Auxilin, which led to the 
hypothesis that PTEN also regulates tumor invasion 
and metastasis [9]. PTEN is one of the most 
common targets for mutation in scattered human 
cancers, which in terms of mutation frequency is 
equal and compete with P53 and , so that after the 
discovery of P53 in 1985, no other genes have been 
remarkable except PTEN [8]. PTEN homozygote 
removal is observed in 10% of cancers. PTEN 
deactivating mutations have been reported in 33-
83% in uterus cancer and 20-55% in uterine 
hyperplasia, suggesting that the gene is also 
effective at the early stages of tumor formation. 
WT et al. in 2014 identified the deactivation of the 
PTEN tumor inhibitor gene in various gastric 
cancer. One of the factors that causes the gene to be 
inactivated include gene mutation, promoter 
hypermethylation, post-translation phosphorylation 
and ineffective heterozygote [10]. In 2013, Canbey 
et al. examined the association between PTENIVS4 
polymorphism and gastric cancer in a Turkish 
population (with 93 patients and 113 healthy 
subjects). They found that PTENIVS4 genotype 
polymorphism increased the risk of gastric cancer 
compared to control subjects significantly [11]. 
Xiang et al in 2015 found that increased expression 
of FAS (fatty acid synthase) and decreased PTEN 
expression may include the spread of peritoneal, 
which is involved in the progression of gastric 
cancer. In 2004, Zhoa et al. examined the 
expression of PTEN / MMAC (1) / TEP (1) and 
VEGF, as well as their role in angiogenesis and 
their association with gastric cancer, which 
observed deactivation of PTEN gene and increased 
the expression of VEGF in gastric cancer. Finally, 
it was suggested that PTEN and VEGF can show 
the biological behavior of the tumor and be used as 
biomarkers [12]. GUO et al. (2006) studied the 
protein expression with the PCR-SSCP-DNA 
sequence method in discovering the PTEN gene 
mutation and its value of gastric cancer, in the 
detection of protein was examined by 
immunohistochemical isolation in cancerous and 
non-cancerous tissues. According to their data, the 
overall positive expression of PTEN protein in the 
gastric cancer tissue was 66%, which was 
significantly lower of non-cancerous tissues. 
Finally, it was suggested that PTEN gene mutation 
may play an important role in the incidence of 
gastric cancer. In 2008, GeH et al investigated the 
PTEN polymorphisms and the incidence of 
esophageal and gastric cancer in China, suggesting 
that 2 common IVS4 (-/+) and -9 (C/G) 
polymorphisms could alter the sensitivity of the 
disease. This investigation of PTEN 
polymorphisms was genotyped by PCR-RFLP. The 
results showed that the risk of esophageal and 
gastric cancer increased significantly after adjusting 
based on age and sex and smoking in people with a 
positive family history of upper gastrointestinal 
cancers [13]. The current study as well as past 
reports suggest that the prediction of the outcome 
in patients with cancer is a complicated and 
complex problem. In addition, the progression of 
the disease is associated with an increased risk of 
death from the disease. The results of this study 
showed that PTEN gene expression can play a role 
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in the early diagnosis of gastric cancer as a 
biological marker. This content provides basic 
information on the role of PTEN, and more 
extensive studies are needed to confirm the precise 
role of this factor. 
 
CONCLUSION: 
According to this study , reduced PTEN gene 
expression is a possible etiology of stomach cancer 
and its progression 
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